Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance.

Previous studies have reported an association between ABO type blood group and cardiovascular (CV) events and outcomes. The precise mechanisms underpinning this striking observation remain unknown, although differences in von Willebrand factor (VWF) plasma levels have been proposed as an explanation. Recently, galectin-3 was identified as an endogenous ligand of VWF and red blood cells (RBCs) and, therefore, we aimed to explore the role of galectin-3 in different blood groups.

Pectins from various sources inhibit galectin-3-related cardiac fibrosis.

Purpose Of The Study: A major challenge in cardiology remains in finding a therapy for cardiac fibrosis. Inhibition of galectin-3 with pectins attenuates fibrosis in animal models of heart failure. The purpose of this study is to identify pectins with the strongest galectin-3 inhibitory capacity.

Development and Assessment of the SMAP Enhanced Passive Soil Moisture Product.

Launched in January 2015, the National Aeronautics and Space Administration (NASA) Soil Moisture Active Passive (SMAP) observatory was designed to provide frequent global mapping of high-resolution soil moisture and freeze-thaw state every two to three days using a radar and a radiometer operating at L-band frequencies. Despite a hardware mishap that rendered the radar inoperable shortly after launch, the radiometer continues to operate nominally, returning more than two years of science data that have helped to improve existing hydrological applications and foster new ones. Beginning in late 2016 the SMAP project launched a suite of new data products with the objective of recovering some high-resolution observation capability loss resulting from the radar malfunction.

Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.

Introduction: We recently identified a set of plasma microRNAs (miRNAs) that are downregulated in patients with heart failure in comparison with control subjects. To better understand their meaning and function, we sought to validate these circulating miRNAs in 3 different well-established rat and mouse heart failure models, and correlated the miRNAs to parameters of cardiac function.

Methods: The previously identified let-7i-5p, miR-16-5p, miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-199a-3p, miR-223-3p, miR-423-3p, miR-423-5p and miR-652-3p were measured by means of quantitative real time polymerase chain reaction (qRT-PCR) in plasma samples of 8 homozygous TGR(mREN2)27 (Ren2) transgenic rats and 8 (control) Sprague-Dawley rats, 6 mice with angiotensin II-induced heart failure (AngII) and 6 control mice, and 8 mice with ischemic heart failure and 6 controls.

Variability of biomarkers in patients with chronic heart failure and healthy controls.

Aims: Biomarkers can be used for diagnosis, risk stratification, or management of patients with heart failure (HF). Knowledge about the biological variation is needed for proper interpretation of serial measurements. Therefore, we aimed to determine and compare the biological variation of a large panel of biomarkers in healthy subjects and in patients with chronic HF.

ST2 and Galectin-3: Ready for Prime Time?

ST2 and galectin-3 are emerging biomarkers in the field of heart failure and have been extensively studied, and that whether they provide additional prognostic value on top of the clinical models and the gold standard in HF, (NT-pro)BNP. Our aim was to provide a comprehensive review of these emerging HF-related biomarkers in chronic, acute and incident heart failure. Regardless of the type of heart failure, both biomarkers seem to have an additional effect on top of the clinical model including natriuretic peptides.

Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND.

Background: High baseline galectin-3 levels are associated with increased risk for adverse cardiovascular outcomes in the general population, but determinants of changes in galectin-3 levels over time have not been established. Therefore, we aimed to identify determinants of (temporal) change in galectin-3 levels.

Methods: Galectin-3 plasma levels were measured in a large community based cohort (PREVEND study) at 3 different time points: at baseline, after ~4 and ~9years.

Serial galectin-3 and future cardiovascular disease in the general population.

Background: Lifetime risk for cardiovascular (CV) disease is high but predicting incident events on an individual level remains difficult. Single measurements of galectin-3, a marker of tissue fibrosis, predict mortality and new-onset heart failure (HF). Persistently elevated levels may indicate a clinically silent disease process.

Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction.

Background: Fibrosis is a pivotal event in infarct repair and progressive remodeling after myocardial infarction (MI). Biomarkers may be used to monitor fibrosis, and therefore we evaluated the predictive value of galectin-3 and sST2 for cardiac remodeling after MI.

Methods: Plasma galectin-3 and sST2 were measured in patients admitted with primary percutaneous coronary intervention (PCI) for acute MI, at baseline and at 4months.

Galectin-3 and post-myocardial infarction cardiac remodeling.

This review summarizes the current literature regarding the involvement and the putative role(s) of galectin-3 in post-myocardial infarction cardiac remodeling. Post-myocardial infarction remodeling is characterized by acute loss of myocardium, which leads to structural and biomechanical changes in order to preserve cardiac function. A hallmark herein is fibrosis formation, both in the early and late phase following acute myocardial infarction.

Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy.

Galectin-3 activation is involved in the pathogenesis of renal damage and fibrogenesis. Limited data are available to suggest that galectin-3-targeted intervention is a potential therapeutic candidate for the prevention of chronic kidney disease. Homozygous TGR(mREN)27 (REN2) rats develop severe high blood pressure (BP) and hypertensive end-organ damage, including nephropathy and heart failure.

Galectin-3 and heart failure: prognosis, prediction & clinical utility.

Heart failure (HF) is a leading cause of mortality in the western world. Despite advances in the treatment of HF, like the use of angiotensin-converting enzyme (ACE) inhibitors, β-blockers, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and implantable cardiac defibrillators, prognosis of HF patients remains poor. For clinicians dealing with HF patients, risk prediction in both acute, chronic, and new onset HF remains a challenge.

Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.

Background: Galectin-3 is a biomarker for prognostication and risk stratification of patients with heart failure (HF). It has been suggested that renal function strongly relates to galectin-3 levels. We aimed to describe galectin-3 renal handling in HF.

Biomarkers for risk prediction in acute decompensated heart failure.

Risk prediction in patients admitted with acute decompensated heart failure (ADHF) remains a challenge. Biomarkers may improve risk prediction, which in turn may help to better inform patients regarding short-term and long-term prognosis, therapy and care. Most data on biomarkers have been derived from patient cohorts with chronic heart failure.

Galectin-3: a modifiable risk factor in heart failure.

Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure. The expression level of galectin-3 mirrors the progression and severity of heart failure and therefore, galectin-3 is being used as a biomarker for heart failure. However, as galectin-3 is causally involved in pathological myocardial fibrosis it has been suggested that galectin-3 also actively contributes to heart failure development.

The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.

Heart failure (HF) is a common disease and affects millions of patients worldwide. Diagnosis, risk assessment and treatment of HF are difficult and therefore there is a need for additional tools to improve clinical performance. Biomarkers may be helpful in this respect.

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

Background: In several cross-sectional analyses, circulating baseline levels of galectin-3, a protein involved in myocardial fibrosis and remodeling, have been associated with increased risk for morbidity and mortality in patients with heart failure (HF). The importance and clinical use of repeated measurements of galectin-3 have not yet been reported.

Methods And Results: Plasma galectin-3 was measured at baseline and at 3 months in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial (n=1329), and at baseline and at 6 months in patients enrolled in the Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) trial (n=324).

Ensemble uncertainty of inherent optical properties.

We present a method to evaluate the combined accuracy of ocean color models and the parameterizations of inherent optical proprieties (IOPs), or model-parametrization setup. The method estimates the ensemble (collective) uncertainty of derived IOPs relative to the radiometric error and is directly applicable to ocean color products without the need for inversion. Validation shows a very good fit between derived and known values for synthetic data, with R(2) > 0.

L band brightness temperature observations over a corn canopy during the entire growth cycle.

During a field campaign covering the 2002 corn growing season, a dual polarized tower mounted L-band (1.4 GHz) radiometer (LRAD) provided brightness temperature (T(B)) measurements at preset intervals, incidence and azimuth angles. These radiometer measurements were supported by an extensive characterization of land surface variables including soil moisture, soil temperature, vegetation biomass, and surface roughness.

Impact of Soil Moisture Dynamics on ASAR σ Signatures and Its Spatial Variability Observed over the Tibetan Plateau.

This paper reports on the analysis of a 2.5 year-long time series of ASAR wide swath mode (WSM) observations for characterizing the soil moisture dynamics. The employed ASAR WSM data set consists of 152 VV-polarized scenes acquired in the period between April 2005 and September 2007 over the Naqu river basin located on the Tibetan Plateau.

Estimation of the Total Atmospheric Water Vapor Content and Land Surface Temperature Based on AATSR Thermal Data.

The total atmospheric water vapor content (TAWV) and land surfacetemperature (LST) play important roles in meteorology, hydrology, ecology and some otherdisciplines. In this paper, the ENVISAT/AATSR (The Advanced Along-Track ScanningRadiometer) thermal data are used to estimate the TAWV and LST over the Loess Plateauin China by using a practical split window algorithm. The distribution of the TAWV isaccord with that of the MODIS TAWV products, which indicates that the estimation of thetotal atmospheric water vapor content is reliable.